- For Patients
- Introduction to the Marshall Protocol
- Length of the MP
- Immunopathology
- Managing immunopathology
- Food and drink
- Light restriction
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Starting the Marshall Protocol
- Resources for patients
- Marshall Protocol summary
- Palliative vs. curative treatments
- Patient interviews on Bacteriality
- Non-MP treatments
- Glossary
- The Protocol
- Marshall Protocol summary
- Publications and presentations
- Science behind immunopathology
- Science behind olmesartan (Benicar)
- Safety of olmesartan
- Resources for physicians
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Physicians' concerns about the MP
- Notice for emergency medical personnel
- The Pathogenesis
- Publications and presentations
- Science behind Marshall Pathogenesis
- Microbes in the human body
- Successive infection and variability in disease
- Autoimmune theory of disease
- Science behind vitamin D
- Metabolism of vitamin D and the VDR
- Th1 Spectrum Disorder - how chronic inflammatory diseases are related
- Transmission of bacteria and onset of chronic disease
- Evolutionary perspective on disease
- Incidence and prevalence of disease
- Evidence that chronic disease is caused by pathogens
- Diseases
- Foundation
- Related Sites
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
| home:protocol:olmesartan:kidney_disease [02.04.2017] – [Benefits of olmesartan for patients with kidney disease] sallieq | home:protocol:olmesartan:kidney_disease [10.13.2018] – [Animal studies] sallieq | ||
|---|---|---|---|
| Line 86: | Line 86: | ||
| {{tag> | {{tag> | ||
| - | ==== Further reading | + | ==== Animal studies |
| Ability to affect the local renin-angiontensin sytem (RAS) and thus improve renal injury and function in a rat model of potentially progressive glomerulosclerosis.(({{pubmed> | Ability to affect the local renin-angiontensin sytem (RAS) and thus improve renal injury and function in a rat model of potentially progressive glomerulosclerosis.(({{pubmed> | ||
| Line 92: | Line 92: | ||
| Ability of Olmesartan to ameliorate renal injury and fibrosis in rats when taken at ultrahigh doses.(({{pubmed> | Ability of Olmesartan to ameliorate renal injury and fibrosis in rats when taken at ultrahigh doses.(({{pubmed> | ||
| + | |||
| + | {{tag> | ||
| ===== Notes and comments ===== | ===== Notes and comments ===== | ||
home/protocol/olmesartan/kidney_disease.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.